Review



ret py905  (Cell Signaling Technology Inc)


Bioz Verified Symbol Cell Signaling Technology Inc is a verified supplier
Bioz Manufacturer Symbol Cell Signaling Technology Inc manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 86

    Structured Review

    Cell Signaling Technology Inc ret py905
    Ret Py905, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+ret+antibody/pm41921856-77-26-21
    Average 86 stars, based on 1 article reviews
    ret py905 - by Bioz Stars, 2026-09
    86/100 stars

    Images

    Related Articles

    Generated:

    Article Title: GFRAL is the receptor for GDF15 and the ligand promotes weight loss in mice and nonhuman primates.
    Article Snippet: Obesity is a global health problem that predisposes people to diseases such as type 2 diabetes, cardiovascular disease, osteoarthritis and cancer.. Worldwide, 1.9 billion people are classified as overweight and 600 million as obese; obesity exerts a substantial burden on healthcare costs1.. Pharmacotherapy is an option for adults with a body-mass index (BMI) of ≥30, or with a BMI between 27 and 29 along with one comorbidity.

    Staining:

    Article Title: Reciprocal Spatiotemporally Controlled Apoptosis Regulates Wolffian Duct Cloaca Fusion
    Article Snippet: .. Embryos were stained with metal-enhanced DAB (#34065; Thermo Fisher Scientific) with an anti-RET antibody (#C31B4, 1:50; Cell Signaling Technology) and secondarily stained with osmium tetraoxide and uranyl acetate to provide intrinsic contrast and enhance the DAB stain. ..

    Article Title: Reciprocal Spatiotemporally Controlled Apoptosis Regulates Wolffian Duct Cloaca Fusion
    Article Snippet: .. Three-Dimensional X-Ray Nano-Computed Tomography Imaging Embryos were stained with metal-enhanced DAB (#34065; Thermo Fisher Scientific) with an anti-RET antibody (#C31B4, 1:50; Cell Signaling Technology) and secondarily stained with osmium tetraoxide and uranyl acetate to provide intrinsic contrast and enhance the DAB stain. ..

    Produced:

    Article Title: RET mutation and increased angiogenesis in medullary thyroid carcinomas
    Article Snippet: 199 200 Western blot analysis and Human Phospho-RTK array 201 Total protein was extracted from TT and MZ-CRC1 cells using a buffer consisting of 150 mmol l - 202 1 Tris HCL pH7.4, 50 mmol l -1 NaCl, Triton 1%, EDTA 20 mmol l -1 , glycerol 5%, protease inhibitor 203 cocktail (PIERCE, Thermo Fisher Scientific), 2 mmol l -1 PMSF, and 2 μg/ml leupeptin. .. RET protein was 204 detected with monoclonal anti-RET antibody (Cell Signaling #3220) produced in rabbits (dilution 205 1:1000). .. Phosphorylated and total ERK protein were detected with monoclonal anti phospho-ERK1/2 206 (Thr202/Tyr204) antibody (Cell Signaling #4370) and with monoclonal anti-ERK1/2 antibody (Cell 207 Signaling #4695), both produced in rabbits (dilution 1:2000 and 1:1000).

    Immunoprecipitation:

    Article Title: RET activation controlled by MAB21L4-CacyBP interaction drives squamous cell carcinoma
    Article Snippet: The gel beads were washed 3 times in cold TBS containing protease inhibitors (Sigma-Aldrich) and then eluted in 2X Laemmli Buffer (Bio-Rad) followed by western blotting. .. RET was immunoprecipitated from 293T cells by incubating 95% of the lysate with Dynabeads Protein G (Invitrogen, 10003D) conjugated to anti-RET antibody (Cell Signaling Technology, 3223). .. RNA was extracted using the RNeasy Plus Mini Kit (Qiagen) according to the manufacturer’s instructions and reverse transcribed to cDNA using iScript reverse transcriptase per the manufacturer’s protocol (Bio-Rad).

    Article Title: MAB21L4 Deficiency Drives Squamous Cell Carcinoma via Activation of RET
    Article Snippet: The gel beads were washed three times in cold TBS containing protease inhibitors (Sigma-Aldrich) and then eluted in 2X Laemmli Buffer (Bio-Rad) followed by Western blotting. .. RET was immunoprecipitated from 293T or A431 cells by incubating 95% of the lysate with Dynabeads Protein G (Invitrogen, 10003D) conjugated to anti-RET antibody (Cell Signaling Technology, 3223). qRT-PCR RNA was extracted using the RNeasy Plus Mini Kit (Qiagen) and reverse transcribed to cDNA using iScript reverse transcriptase (BioRad) per the manufacturer’s instructions. qPCR was performed on a Roche LightCycler 480 II using the SYBR green kit (Thermo Fisher Scientific). ..

    Quantitative RT-PCR:

    Article Title: MAB21L4 Deficiency Drives Squamous Cell Carcinoma via Activation of RET
    Article Snippet: The gel beads were washed three times in cold TBS containing protease inhibitors (Sigma-Aldrich) and then eluted in 2X Laemmli Buffer (Bio-Rad) followed by Western blotting. .. RET was immunoprecipitated from 293T or A431 cells by incubating 95% of the lysate with Dynabeads Protein G (Invitrogen, 10003D) conjugated to anti-RET antibody (Cell Signaling Technology, 3223). qRT-PCR RNA was extracted using the RNeasy Plus Mini Kit (Qiagen) and reverse transcribed to cDNA using iScript reverse transcriptase (BioRad) per the manufacturer’s instructions. qPCR was performed on a Roche LightCycler 480 II using the SYBR green kit (Thermo Fisher Scientific). ..

    Reverse Transcription:

    Article Title: MAB21L4 Deficiency Drives Squamous Cell Carcinoma via Activation of RET
    Article Snippet: The gel beads were washed three times in cold TBS containing protease inhibitors (Sigma-Aldrich) and then eluted in 2X Laemmli Buffer (Bio-Rad) followed by Western blotting. .. RET was immunoprecipitated from 293T or A431 cells by incubating 95% of the lysate with Dynabeads Protein G (Invitrogen, 10003D) conjugated to anti-RET antibody (Cell Signaling Technology, 3223). qRT-PCR RNA was extracted using the RNeasy Plus Mini Kit (Qiagen) and reverse transcribed to cDNA using iScript reverse transcriptase (BioRad) per the manufacturer’s instructions. qPCR was performed on a Roche LightCycler 480 II using the SYBR green kit (Thermo Fisher Scientific). ..

    Real-time Polymerase Chain Reaction:

    Article Title: MAB21L4 Deficiency Drives Squamous Cell Carcinoma via Activation of RET
    Article Snippet: The gel beads were washed three times in cold TBS containing protease inhibitors (Sigma-Aldrich) and then eluted in 2X Laemmli Buffer (Bio-Rad) followed by Western blotting. .. RET was immunoprecipitated from 293T or A431 cells by incubating 95% of the lysate with Dynabeads Protein G (Invitrogen, 10003D) conjugated to anti-RET antibody (Cell Signaling Technology, 3223). qRT-PCR RNA was extracted using the RNeasy Plus Mini Kit (Qiagen) and reverse transcribed to cDNA using iScript reverse transcriptase (BioRad) per the manufacturer’s instructions. qPCR was performed on a Roche LightCycler 480 II using the SYBR green kit (Thermo Fisher Scientific). ..

    SYBR Green Assay:

    Article Title: MAB21L4 Deficiency Drives Squamous Cell Carcinoma via Activation of RET
    Article Snippet: The gel beads were washed three times in cold TBS containing protease inhibitors (Sigma-Aldrich) and then eluted in 2X Laemmli Buffer (Bio-Rad) followed by Western blotting. .. RET was immunoprecipitated from 293T or A431 cells by incubating 95% of the lysate with Dynabeads Protein G (Invitrogen, 10003D) conjugated to anti-RET antibody (Cell Signaling Technology, 3223). qRT-PCR RNA was extracted using the RNeasy Plus Mini Kit (Qiagen) and reverse transcribed to cDNA using iScript reverse transcriptase (BioRad) per the manufacturer’s instructions. qPCR was performed on a Roche LightCycler 480 II using the SYBR green kit (Thermo Fisher Scientific). ..

    Tomography:

    Article Title: Reciprocal Spatiotemporally Controlled Apoptosis Regulates Wolffian Duct Cloaca Fusion
    Article Snippet: .. Three-Dimensional X-Ray Nano-Computed Tomography Imaging Embryos were stained with metal-enhanced DAB (#34065; Thermo Fisher Scientific) with an anti-RET antibody (#C31B4, 1:50; Cell Signaling Technology) and secondarily stained with osmium tetraoxide and uranyl acetate to provide intrinsic contrast and enhance the DAB stain. ..

    Imaging:

    Article Title: Reciprocal Spatiotemporally Controlled Apoptosis Regulates Wolffian Duct Cloaca Fusion
    Article Snippet: .. Three-Dimensional X-Ray Nano-Computed Tomography Imaging Embryos were stained with metal-enhanced DAB (#34065; Thermo Fisher Scientific) with an anti-RET antibody (#C31B4, 1:50; Cell Signaling Technology) and secondarily stained with osmium tetraoxide and uranyl acetate to provide intrinsic contrast and enhance the DAB stain. ..



    Similar Products

    96
    Proteintech ret ab134100
    Ret Ab134100, supplied by Proteintech, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+ret+antibody/beta+Actin+Polyclonal+antibody/pm41933371-114-21-22
    Average 96 stars, based on 1 article reviews
    ret ab134100 - by Bioz Stars, 2026-09
    96/100 stars
      Buy from Supplier

    93
    R&D Systems human fc standard
    Human Fc Standard, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+ret+antibody/Human+Ret+Antibody/pmc13114182-45-3-20
    Average 93 stars, based on 1 article reviews
    human fc standard - by Bioz Stars, 2026-09
    93/100 stars
      Buy from Supplier

    86
    Cell Signaling Technology Inc ret py905
    Ret Py905, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+ret+antibody/pm41921856-77-26-21
    Average 86 stars, based on 1 article reviews
    ret py905 - by Bioz Stars, 2026-09
    86/100 stars
      Buy from Supplier

    86
    Cell Signaling Technology Inc antibody against total ret
    Antibody Against Total Ret, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+ret+antibody/bio_rxiv__64898__2026__03__06__709997-176-3-7
    Average 86 stars, based on 1 article reviews
    antibody against total ret - by Bioz Stars, 2026-09
    86/100 stars
      Buy from Supplier

    94
    Cell Signaling Technology Inc phosphoret tyr 905
    Phosphoret Tyr 905, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+ret+antibody/Ret+Rabbit+mAb/pm41792117-354-34-37
    Average 94 stars, based on 1 article reviews
    phosphoret tyr 905 - by Bioz Stars, 2026-09
    94/100 stars
      Buy from Supplier

    94
    Novus Biologicals 8d12
    8d12, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+ret+antibody/Ret+Antibody+(8D12)/pmc12780286-272-32-42
    Average 94 stars, based on 1 article reviews
    8d12 - by Bioz Stars, 2026-09
    94/100 stars
      Buy from Supplier

    94
    Cell Signaling Technology Inc ret
    Pz-1-based PROTACs activity on <t>CCDC6-RET.</t> TPC1 cells were treated with the indicated PROTACs or Pz-1 for 12 h at the indicated concentrations. Cells were harvested, and extracts were subjected to Western blotting <t>with</t> <t>anti-RET</t> antibody. Tubulin was used as a loading control.
    Ret, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+ret+antibody/Ret+Rabbit+mAb/pmc12647785-55-14-18
    Average 94 stars, based on 1 article reviews
    ret - by Bioz Stars, 2026-09
    94/100 stars
      Buy from Supplier

    86
    Cell Signaling Technology Inc p ret
    Pz-1-based PROTACs activity on <t>CCDC6-RET.</t> TPC1 cells were treated with the indicated PROTACs or Pz-1 for 12 h at the indicated concentrations. Cells were harvested, and extracts were subjected to Western blotting <t>with</t> <t>anti-RET</t> antibody. Tubulin was used as a loading control.
    P Ret, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+ret+antibody/pm41194587-69-12-46
    Average 86 stars, based on 1 article reviews
    p ret - by Bioz Stars, 2026-09
    86/100 stars
      Buy from Supplier

    86
    Cell Signaling Technology Inc ret 3223 p src
    Signaling analysis of pralsetinib and dasatinib combination effects in <t>RET</t> + non‐small cell lung cancer (NSCLC) cells. (A) (Left) Western blot analysis of indicated signaling proteins in CUTO32 cells after treatment with pralsetinib (1 μ m ), dasatinib (0.1 μ m ) or their combination for 3 h. (Right) Quantification of pRET ( n = <t>4),</t> <t>pSRC</t> ( n = 3), pPAK1/2 ( n = 4), pERK1/2 ( n = 3), pAKT ( n = 3), and pS6 ( n = 3) blots, normalized by loading controls (Actin or vinculin). (B) (Left) Western blot analysis of indicated signaling proteins after treatment with pralsetinib (1 μ m ), dasatinib (0.1 μ m ) or their combination for 3 h in CUTO32 cells expressing SRC wild‐type (WT) or SRC T341I gatekeeper. (Right) Quantification of pRET ( n = 3), pSRC ( n = 3), pPAK1/2 ( n = 4), pERK1/2 ( n = 3), pAKT ( n = 3), and pS6 ( n = 3) blots, normalized by loading controls (Actin or vinculin). Statistical significance was determined by one‐way ANOVA with Tukey's multiple comparisons; n.s., not significant. Results are shown as mean ± SD.
    Ret 3223 P Src, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+ret+antibody/pmc13060644-64-15-46
    Average 86 stars, based on 1 article reviews
    ret 3223 p src - by Bioz Stars, 2026-09
    86/100 stars
      Buy from Supplier

    Image Search Results


    Pz-1-based PROTACs activity on CCDC6-RET. TPC1 cells were treated with the indicated PROTACs or Pz-1 for 12 h at the indicated concentrations. Cells were harvested, and extracts were subjected to Western blotting with anti-RET antibody. Tubulin was used as a loading control.

    Journal: Scientific Reports

    Article Title: Discovery of a Proteolysis Targeting Chimera for TRKA and RET-derived oncoproteins

    doi: 10.1038/s41598-025-25687-w

    Figure Lengend Snippet: Pz-1-based PROTACs activity on CCDC6-RET. TPC1 cells were treated with the indicated PROTACs or Pz-1 for 12 h at the indicated concentrations. Cells were harvested, and extracts were subjected to Western blotting with anti-RET antibody. Tubulin was used as a loading control.

    Article Snippet: Antibodies for VEGFR2 (2479), phospho-TRKA (Tyr490) (9141), phospho-TRKA (Tyr674/675) (4621), panTRK (A7H6R) (92991) and RET (14698) were from Cell Signaling Technology (Beverly, MA, USA).

    Techniques: Activity Assay, Western Blot, Control

    Compound 9 activity on RET- and TRKA-driven cell proliferation. The indicated cell lines were incubated with vehicle (NT: not treated) or increasing concentrations of compound 9 and counted at the indicated time points. Data are the mean ± SD of a single experiment performed in triplicate. Number of cells plated at Day 0: KM12 (10,000/well); TT (200,000/well); TPC-1 (5000/well); MZ-CRC-1 and Lc-2/ad (100,000/well). IC 50 dose was calculated using PRIZM software (GraphPad Software Inc). Confidence intervals are indicated in brackets.

    Journal: Scientific Reports

    Article Title: Discovery of a Proteolysis Targeting Chimera for TRKA and RET-derived oncoproteins

    doi: 10.1038/s41598-025-25687-w

    Figure Lengend Snippet: Compound 9 activity on RET- and TRKA-driven cell proliferation. The indicated cell lines were incubated with vehicle (NT: not treated) or increasing concentrations of compound 9 and counted at the indicated time points. Data are the mean ± SD of a single experiment performed in triplicate. Number of cells plated at Day 0: KM12 (10,000/well); TT (200,000/well); TPC-1 (5000/well); MZ-CRC-1 and Lc-2/ad (100,000/well). IC 50 dose was calculated using PRIZM software (GraphPad Software Inc). Confidence intervals are indicated in brackets.

    Article Snippet: Antibodies for VEGFR2 (2479), phospho-TRKA (Tyr490) (9141), phospho-TRKA (Tyr674/675) (4621), panTRK (A7H6R) (92991) and RET (14698) were from Cell Signaling Technology (Beverly, MA, USA).

    Techniques: Activity Assay, Incubation, Software

    Signaling analysis of pralsetinib and dasatinib combination effects in RET + non‐small cell lung cancer (NSCLC) cells. (A) (Left) Western blot analysis of indicated signaling proteins in CUTO32 cells after treatment with pralsetinib (1 μ m ), dasatinib (0.1 μ m ) or their combination for 3 h. (Right) Quantification of pRET ( n = 4), pSRC ( n = 3), pPAK1/2 ( n = 4), pERK1/2 ( n = 3), pAKT ( n = 3), and pS6 ( n = 3) blots, normalized by loading controls (Actin or vinculin). (B) (Left) Western blot analysis of indicated signaling proteins after treatment with pralsetinib (1 μ m ), dasatinib (0.1 μ m ) or their combination for 3 h in CUTO32 cells expressing SRC wild‐type (WT) or SRC T341I gatekeeper. (Right) Quantification of pRET ( n = 3), pSRC ( n = 3), pPAK1/2 ( n = 4), pERK1/2 ( n = 3), pAKT ( n = 3), and pS6 ( n = 3) blots, normalized by loading controls (Actin or vinculin). Statistical significance was determined by one‐way ANOVA with Tukey's multiple comparisons; n.s., not significant. Results are shown as mean ± SD.

    Journal: Molecular Oncology

    Article Title: Dual targeting of RET and SRC synergizes in RET fusion‐positive cancer cells

    doi: 10.1002/1878-0261.70155

    Figure Lengend Snippet: Signaling analysis of pralsetinib and dasatinib combination effects in RET + non‐small cell lung cancer (NSCLC) cells. (A) (Left) Western blot analysis of indicated signaling proteins in CUTO32 cells after treatment with pralsetinib (1 μ m ), dasatinib (0.1 μ m ) or their combination for 3 h. (Right) Quantification of pRET ( n = 4), pSRC ( n = 3), pPAK1/2 ( n = 4), pERK1/2 ( n = 3), pAKT ( n = 3), and pS6 ( n = 3) blots, normalized by loading controls (Actin or vinculin). (B) (Left) Western blot analysis of indicated signaling proteins after treatment with pralsetinib (1 μ m ), dasatinib (0.1 μ m ) or their combination for 3 h in CUTO32 cells expressing SRC wild‐type (WT) or SRC T341I gatekeeper. (Right) Quantification of pRET ( n = 3), pSRC ( n = 3), pPAK1/2 ( n = 4), pERK1/2 ( n = 3), pAKT ( n = 3), and pS6 ( n = 3) blots, normalized by loading controls (Actin or vinculin). Statistical significance was determined by one‐way ANOVA with Tukey's multiple comparisons; n.s., not significant. Results are shown as mean ± SD.

    Article Snippet: Primary antibodies against PARP1 (9542), cleaved Caspase‐3 (9661), p27 (2552), p21 (2947), p‐RET (Y905, 3221), RET (3223) p‐SRC (Y419, 2101), SRC (2108), p‐PAK1/2 (S144/S141, 2606), PAK1/2/3 (2604), p‐ERK1/2 (Y204/Y187, 4370), p‐AKT (S473, 9271), AKT (9272), p‐S6 (S235/S236, 4858), S6 (2217), and Vinculin (13901) were acquired from Cell Signaling Technology.

    Techniques: Western Blot, Expressing

    Combination effects of the next‐generation SRC tyrosine kinase inhibitor (TKI) eCF506 with pralsetinib in RET + non‐small cell lung cancer (NSCLC) cells. (A) (Left) Western blotting of indicated signaling proteins in CUTO32 cells after treatment with pralsetinib (1 μ m ), eCF506 (0.1 μ m ) or their combination for 3 h. (Right) Quantification of p‐RET ( n = 3), p‐SRC ( n = 3), pPAK1/2 ( n = 3), pERK1/2 ( n = 3), pAKT ( n = 3), and p‐S6 ( n = 3) blots, normalized by loading controls (Actin or vinculin). (B) (Top) Cell viability of CUTO32 ( n = 3) and LC‐2/Ad ( n = 3) cells upon treatment with RET TKIs alone and in combination with eCF506 (0.1 μ m ) for 3 days. (Bottom) Cell viability and Bliss synergy analysis of RET + NSCLC cells at single concentrations of RET TKIs (0.625 μ m , see gray arrows above) and eCF506 (0.1 μ m ). (C) Clonogenic survival, quantification and Bliss synergy analysis of RET + NSCLC cells ( n = 4 for CUTO32 and n = 3 for LC‐2/Ad) after treatment with pralsetinib (1 μ m ), eCF506 (0.1 μ m ) or their combination for 7 days. (D) Western blotting and quantification of apoptosis markers upon treatment of CUTO32 cells with pralsetinib (1 μ m ), eCF506 (0.1 μ m ) and their combination for 3 days ( n = 3). Statistical significance was determined by one‐way ANOVA with Tukey's multiple comparisons; n.s., not significant. Results are shown as mean ± SD.

    Journal: Molecular Oncology

    Article Title: Dual targeting of RET and SRC synergizes in RET fusion‐positive cancer cells

    doi: 10.1002/1878-0261.70155

    Figure Lengend Snippet: Combination effects of the next‐generation SRC tyrosine kinase inhibitor (TKI) eCF506 with pralsetinib in RET + non‐small cell lung cancer (NSCLC) cells. (A) (Left) Western blotting of indicated signaling proteins in CUTO32 cells after treatment with pralsetinib (1 μ m ), eCF506 (0.1 μ m ) or their combination for 3 h. (Right) Quantification of p‐RET ( n = 3), p‐SRC ( n = 3), pPAK1/2 ( n = 3), pERK1/2 ( n = 3), pAKT ( n = 3), and p‐S6 ( n = 3) blots, normalized by loading controls (Actin or vinculin). (B) (Top) Cell viability of CUTO32 ( n = 3) and LC‐2/Ad ( n = 3) cells upon treatment with RET TKIs alone and in combination with eCF506 (0.1 μ m ) for 3 days. (Bottom) Cell viability and Bliss synergy analysis of RET + NSCLC cells at single concentrations of RET TKIs (0.625 μ m , see gray arrows above) and eCF506 (0.1 μ m ). (C) Clonogenic survival, quantification and Bliss synergy analysis of RET + NSCLC cells ( n = 4 for CUTO32 and n = 3 for LC‐2/Ad) after treatment with pralsetinib (1 μ m ), eCF506 (0.1 μ m ) or their combination for 7 days. (D) Western blotting and quantification of apoptosis markers upon treatment of CUTO32 cells with pralsetinib (1 μ m ), eCF506 (0.1 μ m ) and their combination for 3 days ( n = 3). Statistical significance was determined by one‐way ANOVA with Tukey's multiple comparisons; n.s., not significant. Results are shown as mean ± SD.

    Article Snippet: Primary antibodies against PARP1 (9542), cleaved Caspase‐3 (9661), p27 (2552), p21 (2947), p‐RET (Y905, 3221), RET (3223) p‐SRC (Y419, 2101), SRC (2108), p‐PAK1/2 (S144/S141, 2606), PAK1/2/3 (2604), p‐ERK1/2 (Y204/Y187, 4370), p‐AKT (S473, 9271), AKT (9272), p‐S6 (S235/S236, 4858), S6 (2217), and Vinculin (13901) were acquired from Cell Signaling Technology.

    Techniques: Western Blot